Johns Hopkins accuses drugmakers of 'gaming' orphan drug law
Report urges Congress to cinch up loopholes it says are bleeding away development funds
But not everyone sees the situation as drugmakers extracting big bucks through loopholes. Jimmy Lin, founder of the Rare Genomics Institute sees it as drugmakers taking advantage of the advances in genomic science that has helped them understand how their drugs can help more people.
"Everyone wants to find a rare disease that can also be used for a majority of the population," Lin told CNBC. "Many blockbuster drugs started off as rare indication. If you have something working for one disease, you want to try it for others as well. The drug pipeline for common diseases is drying out, so pharma companies are trying to get creative here."
Read the article here >